A Focused Review on Molecular Signalling Mechanisms of Ginsenosides Anti-Lung Cancer and Anti-inflammatory Activities

Anticancer Agents Med Chem. 2023;23(1):3-14. doi: 10.2174/1871520622666220321091022.

Abstract

Background: Ginseng (Panax ginseng Meyer) is a cultivated medicinal herb that has been widely available in the Asian region since the last century. Ginseng root is used worldwide in Oriental medicine. Currently, the global mortality and infection rates for lung cancer and inflammation are significantly increasing. Therefore, various preventative methods related to the activity of ginsenosides have been used for lung cancer as well as inflammation.

Methods: Web-based searches were performed on Web of Science, Springer, PubMed, and Scopus. A cancer statistical analysis was also conducted to show the current ratio of affected cases and death from lung cancer around the world.

Results: Ginsenosides regulate the enzymes that participate in tumor growth and migration, such as nuclear factor kappa B (NF-κB), mitogen-activated protein kinase (p38 MAPK), c-Jun N-terminal kinase (JNK), extracellular signalregulated kinases 1/2 (ERK1/2), the gelatinase network metalloproteinase-2 (MMP-2/9) and activator protein 1 (AP-1). In addition, ginsenosides also possess anti-inflammatory effects by inhibiting the formation of proinflammatory cytokines (tumor necrosis factor-α) (TNF-α) and interleukin-1β (IL-1β) and controlling the activities of inflammatory signalling pathways, such as NF-κB, Janus kinase2/signal transducer, and activator of transcription 3 (Jak2/Stat3).

Conclusion: In several in vitro and in vivo models, P. ginseng showed potential beneficial effects in lung cancer and inflammation treatment. In this review, we provide a detailed and up-to-date summary of research evidence for antilung cancer and anti-inflammatory protective effects of ginsenosides and their potential molecular mechanisms.

Keywords: Panax ginseng; anti-inflammation; anti-lung cancer; ginsenosides; mitogen-activated protein kinase; signalling pathway.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Inflammatory Agents / pharmacology
  • Ginsenosides* / pharmacology
  • Ginsenosides* / therapeutic use
  • Humans
  • Inflammation / drug therapy
  • Lipopolysaccharides / therapeutic use
  • Matrix Metalloproteinase 2
  • NF-kappa B / metabolism
  • Neoplasms*
  • Tumor Necrosis Factor-alpha

Substances

  • NF-kappa B
  • Ginsenosides
  • Matrix Metalloproteinase 2
  • Anti-Inflammatory Agents
  • Tumor Necrosis Factor-alpha
  • Lipopolysaccharides